Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial (Q40223075)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 December 2015

Language	Label	Description	Also known as
English	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial	scientific article published on 2 December 2015

Statements

scholarly article

1 reference

Europe PubMed Central

18 September 2017

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

18 September 2017

0 references

type-1 diabetes

0 references

0 references

Thomas Fremming Dejgaard

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jens Juul Holst

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Ulrik Pedersen-Bjergaard

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Henrik U Andersen

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Christian Seerup Frandsen

2

object named as

Christian Seerup Frandsen

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Tanja Stenbæk Hansen

3

object named as

Tanja Stenbæk Hansen

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

4

object named as

Thomas Almdal

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Søren Urhammer

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Tonny Jensen

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Andreas Kryger Jensen

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

2 December 2015

1 reference

Europe PubMed Central

18 September 2017

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

221-232

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Temporal patterns in overweight and obesity in Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin hormones and the satiation signal.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide as additional treatment for type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Obesity and health-related quality of life: a cross-sectional analysis of the US population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900436-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(15)00436-2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26656289%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40223075&oldid=1889348175"